The traditional story is that losing weight improves your A1C. Newer data suggests it may also work in reverse — your A1C before you even start the drug could predict how much weight you'll lose.
For years, A1C has been treated purely as an outcome of GLP-1 therapy — a number that improves as you lose weight. A 2025 multivariate analysis on tirzepatide found something that runs the other direction: people with a lower baseline A1C had meaningfully higher odds of achieving large weight loss (≥20% of body weight) than people who started with a higher A1C. In other words, your A1C level going in may help predict how you'll respond, not just measure what happened afterward.
The well-established mechanism goes one direction. GLP-1 drugs reduce appetite and slow digestion, people lose weight, and lower body weight improves insulin sensitivity, which lowers A1C. A 2.5-year real-world study of this exact chain of events found that the amount of weight someone lost was the strongest factor in how much their A1C improved — patients in the group that lost the least weight (or gained weight) saw the smallest glycemic benefit, while patients in the highest weight-loss group reduced their insulin needs while maintaining good blood sugar control. That's the traditional, well-supported causal direction: weight loss leads, A1C follows.
A joint clinical advisory published in 2025 by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society looked at this from the other angle: given everything measured about a patient before they start tirzepatide, what predicts whether they'll be a big responder?
In their multivariate analysis, a lower baseline A1C was associated with roughly 1.6 times higher odds of reaching a 20% body weight reduction — a large, clinically meaningful response. That put baseline A1C in the same predictive company as other known factors: female sex was linked to roughly 2.4 times higher odds of a large response, absence of a hypertension diagnosis with about 1.35 times higher odds, and lower liver enzyme (ALT) levels with about 1.17 times higher odds.
Put simply: two people starting tirzepatide at the same weight might lose meaningfully different amounts, and part of that difference may be explained by where their A1C stood before they ever took the first dose.
Researchers are still working out the mechanism, but a few explanations are plausible and not mutually exclusive:
None of this is fully settled science. It's an association identified in observational and trial data, not a proven cause-and-effect pathway, and the researchers who published it were explicit that individual response still varies widely regardless of baseline A1C.
This isn't a reason to avoid GLP-1 therapy if your A1C runs higher — plenty of people with elevated A1C still achieve substantial weight loss, and the drugs remain effective across the board for glycemic control specifically. What it does suggest is that weight loss expectations might reasonably be calibrated using more than just starting weight and dose. If you and your prescriber know your baseline A1C tends to predict a more modest response, that's useful information for setting realistic goals, choosing a starting dose, or deciding how patiently to titrate before judging whether a drug is "working."
It also reinforces something worth remembering: A1C isn't just a diabetes number. It's turning out to be a piece of the broader metabolic picture that may shape how your body responds to some of the most effective weight-loss medications available. For background on what class of drug is involved and how it was discovered — including the surprising origin story that starts with Gila monster venom — see our history of GLP-1 drugs and full comparison of Ozempic, Wegovy, Mounjaro and Zepbound.